Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

13 Aug 2020 09:28

RNS Number : 0538W
Cenkos Securities PLC
13 August 2020
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cenkos Securities plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Collagen Solutions plc

 

(c) Name of the party to the offer with which exempt principal trader is connected:

Collagen Solutions plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12 August 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ord GBP0.01

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

317,218

0.07

-

-

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

317,218

0.07

-

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ord GBP0.01

Purchases

-

-

-

Ord GBP0.01

Sales

100,000

2.725

2.725

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

13 August 2020

Contact name:

Carla Brayson

Telephone number:

020 7397 8984

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOGPUMPRUPUURW
Date   Source Headline
10th Mar 20152:56 pmRNSDirector/PDMR Shareholding
10th Mar 20157:03 amRNSRegulatory Approvals for Collagen Solutions Client
10th Mar 20157:03 amRNSTrading Statement and Acquisition Update
9th Jan 20157:00 amRNSInvestor Presentation
7th Jan 20154:04 pmRNSHolding(s) in Company
7th Jan 20157:00 amRNSCEO Presents at OneMedForum
5th Jan 20157:00 amRNSContract signed with Globus Medical Inc.
22nd Dec 20147:00 amRNSNew contract to supply Desu Medical
17th Dec 201410:54 amRNSHolding(s) in Company
15th Dec 20147:00 amRNSContract signed with Kyeron
12th Dec 201410:50 amRNSHolding(s) in Company
10th Dec 20147:00 amRNSSouthern Lights Biomaterials Acquisition Completed
24th Nov 201411:48 amRNSGrant of Options
21st Nov 20147:30 amRNSSchedule 1 - Collagen Solutions Plc
21st Nov 20147:00 amRNSAcquisition
21st Nov 20147:00 amRNSChange of Adviser
21st Nov 20147:00 amRNSHalf Yearly Report
22nd Oct 201412:30 pmRNSHolding(s) in Company
17th Oct 20147:00 amRNSJellagen Collaboration
10th Sep 201412:23 pmRNSHolding(s) in Company
3rd Sep 20147:00 amRNSAppointment to Scientific Advisory Board
27th Aug 201411:52 amRNSResult of AGM
29th Jul 20143:19 pmRNSHolding(s) in Company
18th Jul 20147:00 amRNSPosting of Annual Report & Notice of AGM
10th Jul 20147:00 amRNSFinal Results
3rd Jul 20147:00 amRNSChange of Registered Office
10th Jun 20147:00 amRNSExclusive Licencing of Intellectual Property
19th May 20147:00 amRNSProfessor Robert Brown joins as Scientific Adviser
15th May 20147:00 amRNSExcellagen® enters new clinical trial
26th Mar 201410:48 amRNSHolding(s) in Company
3rd Mar 20147:00 amRNSAppointment of Director
27th Dec 201312:25 pmRNSDirector Shareholding
27th Dec 201311:58 amRNSResult of GM
17th Dec 201310:00 amRNSAnnouncement by Cardium Therapeutics
16th Dec 20139:03 amRNSSchedule 1 - Healthcare Investment Opportunities
10th Dec 20137:00 amRNSHalf Yearly Report
10th Dec 20137:00 amRNSProposed acquisition
19th Aug 201311:06 amRNSHolding(s) in Company
1st Aug 20131:43 pmRNSHolding(s) in Company
2nd May 201312:00 pmRNSHolding(s) in Company
22nd Apr 201312:19 pmRNSHolding(s) in Company
9th Apr 201310:57 amRNSHolding in Company
8th Apr 20135:41 pmRNSHolding(s) in Company
5th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.